 Shares of Kamada NASDAQ:KMDA were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were unchanged 0.00 year over year to 0.12, which beat the estimate of 0.06.Revenue of 33,290,000 rose by 24.23 year over year, which beat the estimate of 30,120,000.Outlook Kamada hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.Conference Call Details Date: May 18, 2020View more earnings on KMDATime: 08:30 AMET Webcast URL: Stock Performance Companys 52-week high was at 8.00Companys 52-week low was at 4.40Price action over last quarter: Up 14.17Company Description Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing and marketing of specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX etc. The company has Proprietary products and Distribution segments. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from Proprietary products segment and generates the majority of sales from the United States. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.See more from Benzinga Sohu.com: Q1 Earnings Insights Recap: Sea Q1 Earnings Horizon Global: Q1 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 